reported in clinical trials for dementia and mild cognitive impairment (MCI) which limits assessment of trial applicability.Objective: This analysis will assess the feasibility of using a frailty index (FI) and individual participant data (IPD) to measure frailty in clinical trials for MCI and ...
This study evaluates the application of non-invasive brain stimulation in the treatment of Mild Cognitive Impairment (MCI) in adults aged 55-85. Soterix Medical 1x1 tES device is being used in the study. Access complete clinical trial information here More on Soterix Medical More on Soterix Medic...
Electronic clinical trial registries were also searched (February 2012). RCTs were included where participant selection was made using Petersenet al-defined aMCI. There was no restriction on intervention type or the outcome tested. For each trial, we extracted information on study design, ...
and ADCS-MCI-ADL scores [43]. The second trial is AHEAD 3–45 (NCT04468659), which was initiated in July 2020 as a 4-year trial comprising two substudies, one of which is A3, and the other one is A45. A3 is enrolling 400 people whose amyloid levels are below the brain-wide thresh...
Western Sydney University's NICM Health Research Institute has led a world-first clinical trial in Australia that offers new hope in the treatment of mild cognitive impairment (MCI) among older people. The trial's results, published in the journal Alzhei
The first trial, Clarity AD (NCT03887455), was initiated in March 2019 and was conducted at 250 sites around the world. It reported favorable outcomes for all primary and secondary measures, including ADAS-Cog14, AD Composite Score (ADCOMS), and ADCS-MCI-ADL scores [43]. The second trial...
clinical trial was started in February 2015 to investigate the effect of pioglitazone in high-risk participants with cognitive decline and who had completed the TOMORROW (Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer’s Disease (AD) and Safety and Efficacy ...
“One of the best technologies that we have here at MCI is a total body mapping system. The VECTRA® WB360 is one of the total body mapping systems that create a 3D image of the entire surface of the skin. The VECTRA WB360 helps us take proactive steps in preventing skin cancer, en...
indicating a 7.5 month slowing of progression. Modeling simulations based on the phase 2 trial data suggest that lecanemab may slow the rate of disease progression by 2.5-3.1 years and has the potential to help people remain in the earlier stages of AD for a longer period of time. In addi...
Effects of Music-with-Movement on Cognitive and Physical Performance of People with Potentially Reversible Cognitive Frailty: a Randomised Controlled Trial Not yet recruiting Physical Frailty;Mild Cognitive Impairment (MCI);Cognitive Frailty music-based cognitive-motor dual-task training/exercise;Social Gathe...